JP2013525416A - 神経変性障害の治療のためのｎｍｎモジュレーター - Google Patents

神経変性障害の治療のためのｎｍｎモジュレーター Download PDF

Info

Publication number
JP2013525416A
JP2013525416A JP2013506743A JP2013506743A JP2013525416A JP 2013525416 A JP2013525416 A JP 2013525416A JP 2013506743 A JP2013506743 A JP 2013506743A JP 2013506743 A JP2013506743 A JP 2013506743A JP 2013525416 A JP2013525416 A JP 2013525416A
Authority
JP
Japan
Prior art keywords
nmn
degeneration
modulator
use according
biomarker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2013506743A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013525416A5 (enExample
Inventor
クオルエマン ミチャエル
クオンフォルトイ ルアウラ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
The Babraham Institute
Original Assignee
The Babraham Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Babraham Institute filed Critical The Babraham Institute
Publication of JP2013525416A publication Critical patent/JP2013525416A/ja
Publication of JP2013525416A5 publication Critical patent/JP2013525416A5/ja
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
JP2013506743A 2010-04-27 2011-04-19 神経変性障害の治療のためのｎｍｎモジュレーター Abandoned JP2013525416A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1006961.5A GB201006961D0 (en) 2010-04-27 2010-04-27 NMN modulator
GB1006961.5 2010-04-27
PCT/GB2011/050770 WO2011135332A2 (en) 2010-04-27 2011-04-19 Nmn modulator

Publications (2)

Publication Number Publication Date
JP2013525416A true JP2013525416A (ja) 2013-06-20
JP2013525416A5 JP2013525416A5 (enExample) 2014-06-19

Family

ID=42270852

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013506743A Abandoned JP2013525416A (ja) 2010-04-27 2011-04-19 神経変性障害の治療のためのｎｍｎモジュレーター

Country Status (7)

Country Link
US (1) US20130131111A1 (enExample)
EP (1) EP2563363A2 (enExample)
JP (1) JP2013525416A (enExample)
AU (1) AU2011247078A1 (enExample)
CA (1) CA2796034A1 (enExample)
GB (1) GB201006961D0 (enExample)
WO (1) WO2011135332A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020156463A (ja) * 2019-03-20 2020-10-01 株式会社リコー インビトロで細胞を評価する方法、細胞基板、及び細胞基板の製造方法

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120328526A1 (en) * 2011-06-27 2012-12-27 University Of Maryland, Baltimore Modulation of Nad+ Activity in Neuropathophysiological Conditions and Uses Thereof
CN103961691A (zh) * 2013-02-03 2014-08-06 复旦大学 尼克酰胺磷酸核糖转移酶在制备神经保护药物中的用途
CN104758307A (zh) * 2015-03-16 2015-07-08 邦泰生物工程(深圳)有限公司 Nadh和nmn在制备帕金森病药物或保健品的应用
CA3123215C (en) * 2018-12-19 2024-04-02 Disarm Therapeutics, Inc. Inhibitors of sarm1 in combination with neuroprotective agents
US20220160688A1 (en) * 2019-03-20 2022-05-26 The Johns Hopkins University Inhibition of nampt and/or sarm1 for the treatment of axonal degradation
EP3712253A1 (en) * 2019-03-20 2020-09-23 Ricoh Company, Ltd. Method of in vitro cellular assay, cell circuit board, and method of manufacturing cell circuit board
CN115605207A (zh) * 2020-05-14 2023-01-13 葡默药物技术有限公司（Us） 用于经粘膜给药的固体剂型
CN112569289A (zh) * 2020-12-24 2021-03-30 深圳市旷逸生物科技有限公司 一种含有nmn的帕金森治疗药物及其制备方法
US12364681B2 (en) 2021-01-08 2025-07-22 The Johns Hopkins University Combined MAPK and NAMPT inhibition for treatment of neuron degeneration
CN117582405A (zh) * 2023-11-21 2024-02-23 广东药科大学 一种烟酰胺单核苷酸纳米复乳及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6797478B1 (en) * 1998-03-05 2004-09-28 University Of Cincinnati Method of detecting axonal damage, from associated disease states using tau monoclonal antibodies
CA2462632A1 (en) * 2001-10-01 2003-04-10 Emory University Introduction of the wlds gene for prevention of axonal degeneration in neurological diseases
WO2003082187A2 (en) * 2002-03-26 2003-10-09 Indiana University Purification and cloning of nmn adenylyltranserase and its therapeutic use
WO2004035823A2 (en) * 2002-10-17 2004-04-29 Evotec Neurosciences Gmbh Diagnostic and therapeutic use of the nicotinamide mononucleotide adenylytransferase 2 (nmnat-2) gene and protein for neurodegenerative diseases
CN1964627B (zh) * 2004-06-04 2011-10-19 华盛顿大学 治疗神经病变的方法和组合物
WO2007136744A1 (en) * 2006-05-19 2007-11-29 The Johns Hopkins University Crystal structure of a substrate complex of nampt/pbef/visfatin
WO2008026018A1 (en) * 2006-09-01 2008-03-06 Topotarget Switzerland Sa New method for the treatment of inflammatory diseases
EP2098231A1 (en) * 2008-03-05 2009-09-09 Topotarget Switzerland SA Use of NAD formation inhibitors for the treatment of ischemia-reperfusion injury
CN102186822A (zh) * 2008-08-29 2011-09-14 顶标公司 新脲和硫脲衍生物
GB0902147D0 (en) * 2009-02-10 2009-03-25 Babraham Inst NMNAT2 modulator

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020156463A (ja) * 2019-03-20 2020-10-01 株式会社リコー インビトロで細胞を評価する方法、細胞基板、及び細胞基板の製造方法

Also Published As

Publication number Publication date
AU2011247078A1 (en) 2012-11-08
EP2563363A2 (en) 2013-03-06
US20130131111A1 (en) 2013-05-23
WO2011135332A4 (en) 2012-02-23
WO2011135332A3 (en) 2011-12-22
WO2011135332A2 (en) 2011-11-03
GB201006961D0 (en) 2010-06-09
CA2796034A1 (en) 2011-11-03

Similar Documents

Publication Publication Date Title
US20130131111A1 (en) Nmn modulators for the treatment of neurodegenerative disorders
Xie et al. TREM2 interacts with TDP-43 and mediates microglial neuroprotection against TDP-43-related neurodegeneration
Wilhelm et al. Immune reactivity towards insulin, its amyloid and protein S100B in blood sera of Parkinson's disease patients
JP6166016B2 (ja) 生体分子の濃度を測定するための方法
TWI569014B (zh) 神經退化性疾病個體之抗體可辨識之小分子之鑑定
US20160008380A1 (en) Targeting glutamine metabolism in brain tumors
US20260130908A1 (en) Methods and compounds modifying mitochondrial function
EP2478375B1 (en) Diagnostic agent for parkinson's disease
Horne et al. Secondary processes dominate the quiescent, spontaneous aggregation of α-synuclein at physiological pH with sodium salts
WO2008043725A1 (en) Biomarker in inflammatory disorders
Padayachee et al. Cerebrospinal fluid-induced retardation of amyloid β aggregation correlates with Alzheimer's disease and the APOE ε4 allele
Takei et al. Alteration in peritoneal cells with the chemokine CX3CL1 reverses age-associated impairment of recognition memory
JP2022530651A (ja) アルファ－シヌクレインアッセイ
Chen et al. DNA nanocage-assisted size-selective recognition and quantification toward low-mass soluble β-amyloid oligomers
JP2023509423A (ja) 神経変性状態のためのバイオマーカーとしてのキナーゼ
Gono et al. NR2‐reactive antibody decreases cell viability through augmentation of Ca2+ influx in systemic lupus erythematosus
WO2010092317A1 (en) Nmnat2 modulator
Bateman et al. Stable Isotope Labeling Kinetics in CNS Translational Medicine: Introduction to SILK Technology
JP7704739B2 (ja) 免疫細胞回復のためのアッセイ
Zhu et al. A screening platform based on epitope editing for drug discovery
JP2016525215A (ja) 多発性硬化症（ｍｓ）を監視する方法および予測キット
Um et al. Supplemental Information Alzheimer Amyloid-ß Oligomer Bound to Post-Synaptic Prion Protein Activates Fyn to Impair Neurons
BRAIN AMPA/QUISQUALATE RECEPTOR CAPABLE

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140415

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140415

A762 Written abandonment of application

Free format text: JAPANESE INTERMEDIATE CODE: A762

Effective date: 20140901